[1] FILOSSO PL, FALCOZ PE, SOLIDORO P, et al.The European Society of Thoracic Surgeons (ESTS) lung neuroendocrine tumors (NETs) database[J]. J Thorac Dis, 2018, 10(29): 3528-3532. [2] SYED Y.Surufatinib: first approval[J]. Drugs, 2021, 81(6): 727-732. [3] HUTCHMED. Chi-Med announces the NMPA approval of surufatinib( Sulanda ® in china ) for non-pancreatic neuroendocrine tumors[EB/OL].[2022-08-12]. https://www.hutch-med.com/wp-content/uploads/2020/12/a201230.pdf. [4] HUTCHMED. Surufatinib (Sulanda): Chinese prescribing information[EB/OL]. [2022-08-12].https://www.hutch-med.com/sc/.pipeline-and-products/our-products. [5] TIAN DD,NIE LX,YANG BZ, et al.Progress in opioid receptor and opioids for the treatment of cancer pain[J]. Cancer Research and Clinic(肿瘤研究与临床), 2016, 28(9): 645-648. [6] GAO XH.Literature review of 178 cases of adverse drug reaction induced by oxycodone hydrochloride[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(1): 72-76. [7] CONE EJ, DARWIN WD, BUCHWALD WF, et al.Oxymorphone metabolism and urinary excretion in human, rat, guinea pig ,rabbit, and dog[J]. Drug Metab Dispos, 1983, 11(5): 446-450. [8] KIM JH, KIM JY, LEE N, et al.Gwak HS. The impact of drug interactions on adverse effects of oral oxycodone in male geriatric patients[J]. J Clin Pharm Ther, 2020, 45(5): 976-982. [9] ZHOU JH, NI J, CHENG M, et al.Abstract 4187: preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF1R kinases[J]. American Association for Cancer Research, 2017, 77(13): 4187-4187. [10] XU JM, WANG Y, CHEN YL, et al.Sulfatinib, a novel kinase inhibitor,in patients with advanced solid tumors: results from a phase I study[J]. Oncotarget, 2017, 8(26): 42076-42086. [11] LI K, MA S, MIAO L, et al.Absorption, metabolism and excretion of surufatinib in rats and humans[J]. Curr Drug Metab, 2020, 21(5): 357-367. [12] CUI YJ,YANG J,LIU M, et al.A novel tyrosine kinase inhibitor sulfatinib for the treatment of neuroendocrine neoplasms[J]. Chinese Journal of New Drugs(中国新药杂志), 2022, 31(22): 2218-2222. [13] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clinical Pharmacology and Therapeutics, 1981, 30(2): 239-245. [14] LIU YM,YAO ZX,WANG JY.Pharmacological action and clinical application of hydroxycodone injection[J]. Strait Pharmaceutical Journal(海峡药学), 2015, 27(4): 115-118. [15] DING SY, XU XX, WU ZQ.Effects of CYP3A4 gene polymorphism on analgesia with oxycodone in inhibiting postoperative pain of lumbar surgery[J]. J Southeast Univ(东南大学学报), 2021, 40(6): 790-795. [16] FENG XQ, ZHU LL, ZHOU Q.Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management[J]. J Pain Res, 2017, 24(10): 1225-1239. |